Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
A phase 3 trial of Rinatabart sesutecan in endometrial cancer, run by Genmab, now recruiting.
Overview
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer is a phase 3 interventional study registered as NCT07166094 by Genmab, with 660 participants planned, started 2025-11-28 and due to reach its primary completion in 2029-08. Interventions recorded: Rina-S, IC. Conditions listed: Endometrial Cancer, Recurrent or Progressive Endometrial Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Shares Rinatabart sesutecan, Genmab.
- TrialRAINFOL-01 (Rina-S)
Shares Rinatabart sesutecan, Genmab, Endometrial cancer.
- TrialStudy to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Re
Shares Rinatabart sesutecan, Genmab.
- TrialStudy to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or
Shares Rinatabart sesutecan, Genmab.
- TrialStudy to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
Shares Rinatabart sesutecan, Genmab.
- TrialAn Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Can
Shares Rinatabart sesutecan, Genmab.
- TargetFolate receptor alpha
Shares Rinatabart sesutecan, Endometrial cancer.